We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| E-therapeutics Plc | ETX | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 9.00 | 00:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 9.00 | 9.00 |
| Industry Sector |
|---|
| PHARMACEUTICALS & BIOTECHNOLOGY |
| Top Posts |
|---|
Posted at 12/4/2024 06:49 by 1347 Yes, good points. I'm not sure why any fund manager would say: I'll invest in a company but only if it's not listed? If you believe the company has serious prospects then what is the downside as an investor/fund manager to it being listed? Seems more to me that existing large shareholders prefer it to be unlisted as then there is less scrutiny. Makes you wonder eh?As for the NASDAQ listing, well the pre-cursor to that is usually an OTC listing, well they had that but then delisted at the end of 27 December 2023. They gave just 4 days notice over the Christmas/New Year period, so if there were many Americans interested in the company and taking a stake then they'll be hacked off I would imagine, as are the UK PIs now. As far as AI is concerned, well I can see the potential and it's a field I've worked in, but there's an awful lot of hype/rubbish being spouted about it at the moment, including by ETX I suspect. Ask yourself this, why have they only ever had a few contracts on the go paying relatively small milestone payments after all these years? Go and look at the last Business Update in January 2024 then look at what's happened since. By the way if you chose to hold then if it's anything like Deepmatter, which I suspect it will be as Griffin was behind both, then as a minority shareholder you are not going to get much, if anything, in the way of updates and so are very likely not going to realise what's going on until it's too late. I got just a few hours notice when they did the placing and consolidation at Deepmatter that wiped all but the biggest shareholders out. Personally after this behaviour I wouldn't touch anything Ali's involved in or Griffin is a large shareholder in with a bargepole, even if they discovered eternal life, but that's just my opinion, others should DYOR as they say. |
Posted at 12/4/2024 06:11 by pireric Very much agree with The Millipede/1347Nice excuse to complain that fund managers don't understand the potential risk reward in companies in this space. Most are serial destructors of shareholder value while management get paid richly. Hence they want to go to the US which seems all too happy to throw cash at ventures in the hope that one in 5/10 turns into a multibagger to justify the other failures. Or just to ride the coattails of US retail investors who are happy to pump and dump whatever the latest theme is If they really cared about investors they would have: 1) bought out the minorities or at least put a tender offer in place 2) evaluated a US listing mechanism while keeping ETX listed in the meantime Instead they are just annoying a large proportion of the retail shareholder base. Question around their fiduciary duty to force a bunch to sell at valuations which they self-believe are too low. Eric (no holding, never have) |
Posted at 11/4/2024 18:26 by the millipede Ali - I am not invested here and I don’t know what I would do in your shoes.Might depend on my time horizon. But note there is no promise at all of any future listing so if my horizon were not very long I think I would look to exit. As takeiteasy suggests this move is really about etx being able to raise more capital = more dilution, rather than necessarily any benefit for current shareholders. Silence’s share price has not risen at all since moving to Nasdaq (once you account for the 3:1 consolidation and exchange rate) and at times recently has in fact traded far lower. You are right to say the vote might not go through. Would be worth also checking with your broker about what would happen to your holding on delisting. This is not advice. I am here because I wondered briefly about buying some shares for my SIPP which I won’t need for a few decades. But having looked, I think I will pass. ATB and good luck, TM |
Posted at 31/1/2024 13:12 by dplewis1 Similar line of work to ETX -https://techfunding |
Posted at 28/9/2023 14:00 by 1347 What'a this got to do with ETX? |
Posted at 25/9/2023 12:06 by 1347 Do ETX do anything, or have they become just another placings today, jam tomorrow company? I hope it's not going the same way as DeepMatter, it was a disgrace what happened there and I note Griff is involved in both. Ali needs to get his finger out and let shareholders know what they are doing, if anything. |
Posted at 13/7/2023 10:01 by maccamcd Have you all seen this news???Recursion Pharmaceuticals (RXRX.NQ) strikes computational drug discovery deal with Nvidia (NVDA.NQ). • Recursion Pharmaceuticals, an AI drug discovery business, announced a collaboration and $50m equity investment by Nvidia. • Under the agreement, the partners aim to use Recursion’s biological and chemical datasets to accelerate the training of computational models on Nvidia’s platform. • These models could be used for commercial license/release on BioNeMo, NVIDIA’s cloud service for generative AI in drug discovery. • Recursion also expects to use this software to support its internal pipeline and its current and future partners. The agreement demonstrates the continued interest of generative AI in drug discovery. BioNeMo incorporates large language models (LLMs) into its platform. LLMs, such as Chat GPT-4, are a type of AI trained on large datasets to perform a wide range of tasks, such as generating new hypotheses, predicting protein-protein interactions as well as analysing biomedical literature and patent information at scale. Although LLMs show promise in improving drug discovery activities, few companies have integrated this technology into their operations. The slow adoption of LLMs in the pharmaceutical industry leaves a significant opportunity for first movers to capture interest in this area. On AIM, ETX is integrating Large Language Models (LLMs) into its own platform. |
Posted at 03/7/2023 09:28 by maccamcd this Companymeet presentation should be informative! Hopefully Ali gives colour on the speed of larger biotech jv interest. At the moment it's hard to quantify what this AI boom really means for ETX in $You all registered? |
Posted at 23/5/2023 14:02 by bloomberg2 ETX get on it while it's under the radar |
Posted at 25/10/2021 13:44 by ali47fish etx reports tomorrow and and a presentation- anyone knows hoot access the latter please |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
